First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD StudyEduardo Díaz‐Rubio, Auxiliadora Gómez‐España, Bartomeu Massutí et al.|The Oncologist|2012Cited by 213
Circulating Tumor Cell Count Is a Prognostic Factor in Metastatic Colorectal Cancer Patients Receiving First-Line Chemotherapy Plus Bevacizumab: A Spanish Cooperative Group for the Treatment of Digestive Tumors StudyJavier Sastre, Eduardo Díaz‐Rubio, M.L. Maestro et al.|The Oncologist|2012Cited by 88
ColoLipidGene: signature of lipid metabolism-related genes to predict prognosis in stage-II colon cancer patientsTeodoro Vargas, Ana Ramı́rez de Molina, Juan Moreno‐Rubio et al.|Oncotarget|2015Cited by 76
A Combined Strategy of SAGE and Quantitative PCR Provides a 13-Gene Signature that Predicts Preoperative Chemoradiotherapy Response and Outcome in Rectal CancerE. Casado, Paloma Cejas, José Javier Sánchez et al.|Clinical Cancer Research|2011Cited by 32
First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD StudyEduardo Díaz‐Rubio, Enrique Aranda, Auxiliadora Gómez‐España et al.|Unknown|2012Cited by 25